104 related articles for article (PubMed ID: 7890253)
41. [Hormone replacement therapy with transdermal estradiol lowers insulin-cortisol and lipoproteins levels in postmenopausal women].
Basurto L; Saucedo R; Ochoa R; Hernández M; Zárate A
Ginecol Obstet Mex; 2002 Oct; 70():491-5. PubMed ID: 12557803
[TBL] [Abstract][Full Text] [Related]
42. A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women.
Shifren JL; Desindes S; McIlwain M; Doros G; Mazer NA
Menopause; 2007; 14(6):985-94. PubMed ID: 17507833
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of tibolone and transdermal estrogen therapy on psychological symptoms in women following surgical menopause.
Baksu A; Ayas B; Citak S; Kalan A; Baksu B; Goker N
Int J Gynaecol Obstet; 2005 Oct; 91(1):58-62. PubMed ID: 15970290
[TBL] [Abstract][Full Text] [Related]
44. A switch from oral (2 mg/day) to transdermal (50 microg/day) 17beta-estradiol therapy increases serum insulin-like growth factor-I levels in recombinant human growth hormone (GH)-substituted women with GH deficiency.
Janssen YJ; Helmerhorst F; Frölich M; Roelfsema F
J Clin Endocrinol Metab; 2000 Jan; 85(1):464-7. PubMed ID: 10634425
[TBL] [Abstract][Full Text] [Related]
45. Acute alcohol intake and pituitary gonadal hormones in normal human females.
Mendelson JH; Mello NK; Ellingboe J
J Pharmacol Exp Ther; 1981 Jul; 218(1):23-6. PubMed ID: 7241380
[TBL] [Abstract][Full Text] [Related]
46. A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women.
Shifren JL; Rifai N; Desindes S; McIlwain M; Doros G; Mazer NA
J Clin Endocrinol Metab; 2008 May; 93(5):1702-10. PubMed ID: 18303079
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol.
Scott RT; Ross B; Anderson C; Archer DF
Obstet Gynecol; 1991 May; 77(5):758-64. PubMed ID: 2014092
[TBL] [Abstract][Full Text] [Related]
48. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
Stephenson K; Neuenschwander PF; Kurdowska AK
Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
[TBL] [Abstract][Full Text] [Related]
49. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Rozenberg S; Ylikorkala O; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
[TBL] [Abstract][Full Text] [Related]
50. [Effect of a 17 beta estradiol gel preparation on hormone levels in menopausal women].
Araya V; Contreras P; Aguirre C; Foradori A
Rev Med Chil; 1995 Sep; 123(9):1116-21. PubMed ID: 8728735
[TBL] [Abstract][Full Text] [Related]
51. [Changes in C-reactive protein levels induced by different application forms of estrogen replacement therapy].
Fait T; Vrablík M; Kostírová M; Trnková B
Cas Lek Cesk; 2006; 145(7):571-4; discussion 574. PubMed ID: 16921788
[TBL] [Abstract][Full Text] [Related]
52. Effect of hormone therapy on the enteroinsular axis.
Sztefko K; Rogatko I; Milewicz T; Józef K; Tomasik PJ; Szafran Z
Menopause; 2005; 12(5):630-638. PubMed ID: 16145319
[TBL] [Abstract][Full Text] [Related]
53. A decade of experience with transdermal estrogen replacement therapy: overview of key pharmacologic and clinical findings.
Corson SL
Int J Fertil; 1993; 38(2):79-91. PubMed ID: 8097503
[TBL] [Abstract][Full Text] [Related]
54. Do different delivery systems of hormone therapy have different effects on psychological symptoms in surgically menopausal women? A randomized controlled trial.
Baksu B; Baksu A; Göker N; Citak S
Maturitas; 2009 Feb; 62(2):140-5. PubMed ID: 19179026
[TBL] [Abstract][Full Text] [Related]
55. An Australian experience of transdermal oestradiol patches in a subtropical climate.
O'Neill S; Kirkegard Y
Aust N Z J Obstet Gynaecol; 1993 Aug; 33(3):327-9. PubMed ID: 8304906
[TBL] [Abstract][Full Text] [Related]
56. Acute alcohol effects on plasma estradiol levels in women.
Mendelson JH; Lukas SE; Mello NK; Amass L; Ellingboe J; Skupny A
Psychopharmacology (Berl); 1988; 94(4):464-7. PubMed ID: 3131791
[TBL] [Abstract][Full Text] [Related]
57. Comparison of gel and patch estradiol replacement in Brazil, a tropical country.
Travassos de Figueiredo Alves ; Amélia Sobreira Gomes M; Clapauch R
Maturitas; 2000 Jul; 36(1):69-74. PubMed ID: 10989244
[TBL] [Abstract][Full Text] [Related]
58. Use of two types of estradiol-releasing skin patches for menopausal patients in a tropical climate.
McCarthy T; Dramusic V; Ratnam S
Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 2):2005-10. PubMed ID: 1605292
[TBL] [Abstract][Full Text] [Related]
59. A prospective study of plasma prolactin levels and subsequent risk of breast cancer.
Kwa HG; Cleton F; Wang DY; Bulbrook RD; Bulstrode JC; Hayward JL; Millis RR; Cuzick J
Int J Cancer; 1981 Dec; 28(6):673-6. PubMed ID: 7333701
[TBL] [Abstract][Full Text] [Related]
60. [Estrogen activity and prolactin secretion in menopausal women at high risk of developing breast cancer].
Teter J; Paszko Z; Kwiatkowska Z; Arsoba-Komarzyńska J
Nowotwory; 1983; 33(4):333-40. PubMed ID: 6672778
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
